Ikeura Y, Tanaka T, Kiyota Y, Morimoto S, Ogino M, Ishimaru T, Kamo I, Doi T, Natsugari H
Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1642-52. doi: 10.1248/cpb.45.1642.
Various N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl heterocycles (1, 2 and 3) modified at rings A and B in the isoquinolone (1a) and pyrido[3,4-b]pyridine (2a) nuclei were prepared and evaluated for NK1 receptor antagonistic activities. The structure-activity relationship studies on this series, along with conformational analysis, showed that (i) for ring A, 6-membered heterocycles are preferable to 5-membered heterocycles (a ca. 300-fold difference in potency), (ii) the 6-membered ring seems to function as an anchor by fixing the pendant phenyl group in a desirable orientation for receptor binding, and (iii) since compounds with aromatic rings (2) and those with aliphatic rings (3) as ring B both show good potency, this ring does not seem to be essential for receptor recognition. Among the compounds synthesized, the tetrahydropyridine derivatives 3a, 3b and 3f exhibited excellent inhibitory effects both in vitro and in vivo, with potent activity upon oral administration (ED50 = 0.20-0.27 mg/kg) (capsaicin-induced plasma extravasation in guinea pig trachea).
制备了异喹啉酮(1a)和吡啶并[3,4-b]吡啶(2a)核中A环和B环修饰的各种N-[3,5-双(三氟甲基)苄基]-N-甲基氨基甲酰基杂环(1、2和3),并对其NK1受体拮抗活性进行了评估。对该系列化合物的构效关系研究以及构象分析表明:(i)对于A环,六元杂环比五元杂环更具优势(效价相差约300倍);(ii)六元环似乎通过将侧链苯基固定在受体结合的理想方向上起到锚定作用;(iii)由于B环为芳环的化合物(2)和B环为脂肪环的化合物(3)均表现出良好的效价,因此该环对于受体识别似乎并非必不可少。在合成的化合物中,四氢吡啶衍生物3a、3b和3f在体内外均表现出优异的抑制作用,口服给药时具有强效活性(ED50 = 0.20 - 0.27 mg/kg)(豚鼠气管中辣椒素诱导的血浆外渗)。